Altimmune (ALT)
NASDAQ:ALT
Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$3.50
$0.16(2.19%)
At close: 4:00 PM EST
$3.50
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.56 - $7.73
Previous CloseN/A
Volume1.55M
Average Volume (3M)4.54M
Market Cap
$548.42M
Enterprise Value$194.19M
Total Cash (Recent Filing)$331.54M
Total Debt (Recent Filing)$35.85M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume3,028,345
30 Day Avg. Volume4,535,136
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue5.39K
Enterprise Value/Gross Profit-12.99
Enterprise Value/Ebitda-2.08
Forecast
1Y Price Target
$13.30Price Target Upside280.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$5.13K
Bulls Say, Bears Say
Bulls Say
Expanded IndicationsProgress in alcohol use disorder and alcohol‑associated liver disease programs could meaningfully expand development and commercial opportunities if upcoming clinical readouts confirm benefit in these underserved indications.
Mechanism Of ActionDual mechanism combining appetite suppression via GLP‑1 activity with direct liver‑fat reduction via glucagon activity could produce superior metabolic and liver outcomes versus GLP‑1‑only therapies, supporting a stronger clinical and commercial case.
Regulatory PathwayRegulatory alignment on key trial parameters together with Breakthrough Therapy Designation creates a clearer path for a pivotal approval program and reduces late‑stage development uncertainty.
Bears Say
Clinical DifferentiationPhase IIb showed therapeutic activity but did not demonstrate clear differentiation from existing treatments, which may hinder the ability to command a premium position in therapy choices.
Competitive LandscapeThe metabolic dysfunction‑associated steatohepatitis market is crowded with established drugs and emerging competitors, increasing pressure on uptake and market share unless the drug shows clear, meaningful advantages.
Development And Financing RiskClinical trial, regulatory, and financing risks introduce substantial uncertainty that could prevent the drug from reaching the market or meeting current valuation expectations.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.56 and its highest was $7.73 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $548.42M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 75 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.15.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -1.948%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.30 (280.00% Upside)
$13.30 (280.00% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $198.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.58%
12-Months-Change
Fundamentals
Return on Equity
-42.57%
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$13.30
▲(280.00% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.45% Insiders
7.72% Mutual Funds
3.21% Other Institutional Investors
78.76% Public Companies and Individual Investors